The government of India approved the commercial export of Bharat Biotech’s Covid-19 vaccine Covaxin on Tuesday.
Covaxin, India’s first indigenous vaccine for Covid-19, has been found to be 77.8 per cent effective against the deadly contagious virus, a report published in The Lancet recently said.
Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) under the research name BBV152, is a Vero cell-derived, inactivated whole-virion vaccine formulated with a novel adjuvant and administered in a two-dose regimen 28 days apart.
The vaccine, which was approved for emergency use in adults in India in January, was granted an Emergency Use Listing (EUL) by the World Health Organization (WHO) on November 3, 2021.
Notably, the UK government has added Bharat Biotech’s Covaxin to its approved list of Covid vaccines for international travellers beginning November 22, 2021.
Prior to giving approval to Covaxin, the WHO had given its nod to Pfizer/BioNTech vaccine, two AstraZeneca/Oxford vaccines manufactured by AstraZeneca-SKBio (Republic of Korea and the Serum Institute of India), Ad26.COV2.S developed by Janssen (Johnson & Johnson) and China’s Sinopharm for emergency use.
As per Bharat Biotech, Covaxin has proven to neutralise the variants – B.1.1.7 (Alpha) first isolated in the United Kingdom, P.1- B.1.1.28 (Gamma) and P.2 – B.1.1.28 (Zeta) first isolated in Brazil, B.1.617 (Kappa) first isolated in India, B.1.351 and B.1.617.2 (Beta & Delta) first isolated in RSA and India. India Today